Skip to main content
SpringerLink
Log in

Special population: Pregnancy, pain and addiction

  • Chapter
  • First Online:
Managing Patients with Chronic Pain and Opioid Addiction

  • 1012 Accesses

Abstract

Women with opioid addiction are often of child bearing years and pregnancy is not uncommon in this population. Most of these pregnancies are unplanned, as it has been reported that 86% of pregnancies in opioid-abusing women are unintended [1]. Even in the nonabusing pregnant patient population, more than 14% will be prescribed opioids at some time during their pregnancy due to pain [2]. Thus, physicians and healthcare teams should know the basic tenets for prescribing opioids and other analgesics during pregnancy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Heil SH, Jones HE, Arria A, et al. Unintended pregnancy in opioid-abusing women. J Subst Abuse Treat. 2011;40:199-202.

    Google Scholar 

  2. Bateman BT, Hernandez-Diaz S, Rathmell JP, et al. Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States. Anesthesiology. 2014;120:1216-1224.

    Google Scholar 

  3. Govindappagari S, Grossman TB, Dayal A, et al. Peripheral nerve blocks in pregnant patients with headache. Obstet Gynecol. 2014;123 Suppl 1:147S.

    Google Scholar 

  4. Broussard CS, Rasmussen SA, Reefhuis J, et al; National Birth Defects Prevention Study. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol. 2011;204:314.e1-e11.

    Google Scholar 

  5. Bracken MB, Holford TR. Exposure to prescribed drugs in pregnancy and association with congenital malformations. Obstet Gynecol. 1981;58:336-344.

    Google Scholar 

  6. Jick H, Holmes LB, Hunter JR, et al. First-trimester drug use and congenital disorders. JAMA. 1981;246:343-346.

    Google Scholar 

  7. Fox AW, Diamond ML, Spierings EL. Migraine during pregnancy: options for therapy. CNS Drugs. 2005;19:465-481.

    Google Scholar 

  8. Babb M, Koren G, Einarson A. Treating pain during pregnancy. Can Fam Physician. 2010;56:25,27.

    Google Scholar 

  9. Jones HE, Heil SH, Baewert A, et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction. 2012;107 Suppl 1:5-27.

    Google Scholar 

  10. Debelak K, Morrone WR, O’Grady KE, Jones HE. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Am J Addict. 2013;22:252-254.

    Google Scholar 

  11. FDA, U.S. Department of Health and Human Services (HHS). Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. 21 CFR Part 201. May 29, 2008. Fed Regist. 2008;73(104):30831-30868.

    Google Scholar 

  12. Thiele K, Kessler T, Arck P, et al. Acetaminophen and pregnancy: short- and long-term consequences for mother and child. J Reprod Immunol. 2013;97:128-139.

    Google Scholar 

  13. Blaser JA, Michael Allan G. Acetaminophen in pregnancy and future risk of ADHD in offspring. Can Fam Physician. 2014;60:642.

    Google Scholar 

  14. Marsh CA, Cragan JD, Alverson CJ, Correa A. Case-control analysis of maternal prenatal analgesic use and cardiovascular malformations: Baltimore-Washington Infant Study. Am J Obstet Gynecol. 2014;211:404.e1-9.

    Google Scholar 

  15. Stuart MJ, Gross SJ, Elrad H, Graeber JE. Effects of acetylsalicylic acid ingestion on maternal and neonatal hemostasis. N Engl J Med. 1982;307:909-912.

    Google Scholar 

  16. Burdan F, Szumilo J, Dudka J, et al. Congenital ventricular septal defects and prenatal exposure to cyclooxygenase inhibitors. Braz J Med Biol Res. 2006;39:925-934.

    Google Scholar 

  17. Hernandez RK, Werler MM, Romitti P, et al; National Birth Defects Prevention Study. Nonsteroidal antiinflammatory drug use among women and the risk of birth defects. Am J Obstet Gynecol. 2012;206:228.e1-e8.

    Google Scholar 

  18. Ives TJ, Tepper RS. Drug use in pregnancy and lactation. Prim Care. 1990;17:623-645.

    Google Scholar 

  19. Norton ME. Teratogen update: fetal effects of indomethacin administration during pregnancy. Teratology. 1997;56:282-292.

    Google Scholar 

  20. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. Baltimore, MD: Williams & Wilkins; 1990.

    Google Scholar 

  21. Van Marter LJ, Hernandez-Diaz S, Werler MM, et al. Nonsteroidal antiinflammatory drugs in late pregnancy and persistent pulmonary hypertension of the newborn. Pediatrics. 2013;131:79-87.

    Google Scholar 

  22. Antonucci R, Zaffanello M, Puxeddu E, et al. Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn. Curr Drug Metab. 2012;13:474-490.

    Google Scholar 

  23. Gentile S. Tricyclic antidepressants in pregnancy and puerperium. Expert Opin Drug Saf. 2014;13:207-225.

    Google Scholar 

  24. Pariante CM, Seneviratne G, Howard L. Should we stop using tricyclic antidepressants in pregnancy? Psychol Med. 2011;41:15-17.

    Google Scholar 

  25. Hoog, SL, Cheng Y, Elpers J, Dowsett SA. Duloxetine and pregnancy outcomes: safety surveillance findings. Int J Med Sci. 2013;10:413-419.

    Google Scholar 

  26. Bellantuono C, Marini A, Lucarelli C. Infant health and neurodevelopmental outcomes following prenatal exposure to duloxetine. Clin Drug Investig. 2013;33:685-688.

    Google Scholar 

  27. Huang H, Coleman S, Bridge JA, et al. A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight. Gen Hosp Psychiatry. 2014;36:13-18.

    Google Scholar 

  28. Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370:2397-2407.

    Google Scholar 

  29. FDA Advising of Risk of Birth Defects with Paxil. FDA News Release. www.fda.gov/newsevents/newsroom/pressannouncements/2005/ucm108527.htm. Published December 8, 2005. Accessed August 18, 2014.

  30. Louik C, Kerr S, Mitchell AA. First-trimester exposure to bupropion and risk of cardiac malformations. Pharmacoepidemiol Drug Saf. 2014;23:1066-1075.

    Google Scholar 

  31. Ornoy A, Koren G. Selective serotonin reuptake inhibitors in human pregnancy: on the way to resolving the controversy. Semin Fetal Neonatal Med. 2014;19:188-194.

    Google Scholar 

  32. Grote NK, Bridge JA, Gavin AR, et al. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry. 2010;67:1012-1024.

    Google Scholar 

  33. Hernández-Díaz S, Smith CR, Shen A, et al; North American AED Pregnancy Registry; North American AED Pregnancy Registry. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78:1692-1699.

    Google Scholar 

  34. Massachusetts General Hospital. Antiepileptic Drug Pregnancy Registry. www.aedpregnancyregistry.org. Accessed January 13, 2015.

  35. Mines D, Tennis P, Curkendall SM, et al. Topiramate use in pregnancy and the birth prevalence of oral clefts. Pharmacoepidemiol Drug Saf. 2014;23:1017-2025.

    Google Scholar 

  36. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol. 2014;261:579-588.

    Google Scholar 

  37. Jentink J, Loane MA, Dolk H, et al; EUROCAT Antiepileptic Study Working Group. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med. 2010;362:2185-2193.

    Google Scholar 

  38. Harden CL, Meador KJ, Pennell PB, et al; American Academy of Neurology; American Epilepsy Society. Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73:133-141.

    Google Scholar 

  39. Morrow J, Russell A, Guthrie E, et al. Malformations risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2006;77:193-198.

    Google Scholar 

  40. Mølgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA. 2011;305:1996-2002.

    Google Scholar 

  41. Ban L, West J, Gibson JE, et al. First trimester exposure to anxiolytic and hypnotic drugs and the risks of major congenital anomalies: a United Kingdom population-based cohort study. PLoS One. 2014;9:e100996.

    Google Scholar 

  42. Bellantuono C, Tofani S, Di Sciascio G, Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. Gen Hosp Psychiatry. 2013;35:3-8.

    Google Scholar 

  43. Gaskell H, Derry S, Moore RA, McQuay HJ. Single dose oral oxycodone and oxycodone plus paracetamol (acetaminophen) for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009;(3):CD002763.

    Google Scholar 

  44. Committee on Health Care for Underserved Women and the American Society of Addiction Medicine. The American College of Obstetricians and Gynecologists Women’s Health Care Physicians. Committee Opinion. Number 524. www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Health-Care-for-Underserved-Women/Opioid-Abuse-Dependence-and-Addiction-in-Pregnancy. Published May 2012. Reaffirmed 2014. Accessed August 18, 2014.

  45. Winklbaur B, Kopf N, Ebner N, et al. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction. 2008;103:1429-1440.

    Google Scholar 

  46. Jones HE, O’Grady KE, Malfi D, Tuten M. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict. 2008;17:372-386.

    Google Scholar 

  47. Coyle MG, Salisbury AL, Lester BM, et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction. 2012;107 Suppl 1:63-73.

    Google Scholar 

  48. Pond SM, Kreek MJ, Tong TG, et al. Altered methadone pharmacokinetics in methadonemaintained pregnant women. J Pharmacol Exp Ther. 1985;233:1-6.

    Google Scholar 

  49. Weaver MF. Perinatal addiction. In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, eds. Principles of Addiction Medicine. 3rd ed. Chevy Chase, MD: Lippincott Williams & Wilkins; 2003:1231-1246.

    Google Scholar 

  50. Jarvis MA, Wu-Pong S, Kniseley JS, Schnoll SH. Alterations in methadone metabolism during late pregnancy. J Addict Dis. 1999;18:51-61.

    Google Scholar 

  51. Stewart RD, Nelson DB, Adhikari EH, et al. The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. Am J Obstet Gynecol. 2013;209:267.e1-e5.

    Google Scholar 

  52. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363:2320-2331.

    Google Scholar 

  53. Lund IO, Skurtveit S, Sarfi M, et al. Substance use during and after pregnancy among a national cohort of pregnant women in opioid maintenance treatment and their partners. J Subst Use. 2012;17:277-286.

    Google Scholar 

  54. Welle-Strand GK, Skurtveit S, Jones HE, et al. Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009. Drug Alcohol Depend. 2013;127:200-206.

    Google Scholar 

  55. Jones HE, Finnegan LP, Kaltenbach K. Methadone and buprenorphine for the management of opioid dependence in pregnancy. Drugs. 2012;72:747-757.

    Google Scholar 

  56. Gibson A, Degenhardt L, Mattick RP, et al. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction. 2008;103:462-468.

    Google Scholar 

  57. Wong S, Ordean A, Kahan M; Society of Obstetricians and Gynecologists of Canada. SOGC clinical practice guidelines: substance use in pregnancy: no. 256, April 2011. Int J Gynaecol Obstet. 2011;114:190-202.

    Google Scholar 

  58. Doberczak TM, Thornton JC, Bernstein J, Kandall SR. Impact of maternal drug dependency on birth weight and head circumference of offspring. Am J Dis Child. 1987;141:1163-1167.

    Google Scholar 

  59. Hulse GK, Milne E, English DR, Holman CD. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction. 1997;92:1571-1579.

    Google Scholar 

  60. Ordean A, Kahan M, Graves L, et al. Integrated care for pregnant women on methadone maintenance treatment: Canadian primary care cohort study. Can Fam Physician. 2013;59:e462-e4629.

    Google Scholar 

  61. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy: effects and management. Obstet General Clin North Am. 1998;25:139-151.

    Google Scholar 

  62. Czerkes M, Blacstone J, Pulvino J. Buprenorphine versus methadone treatment for opiate addiction in pregnancy: an evaluation of neonatal outcomes. Presented at: 2010 58th Annual Clinical Meeting The American College of Obstetricians and Gynecologists; May 15-19, 2010; San Francisco, CA.

    Google Scholar 

  63. Lund IO, Fischer G, Welle-Strand GK, et al. A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes. Subst Abuse. 2013;7:61-74.

    Google Scholar 

  64. Ward J, Mattick RP, Hall W. Methadone maintenance during pregnancy. In: Ward J; Mattick RP; Hall W, eds. Methadone Maintenance Treatment and Other Opioid Replacement Therapies. Amsterdam, The Netherlands: Harwood Academic Publishers; 1998:397-417.

    Google Scholar 

  65. Meyer M, Wagner K, Benvenuto A, et al. Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy. Obstet Gynecol. 2007;110:261-266.

    Google Scholar 

  66. Academy of Breastfeeding Medicine Protocol Committee, Jansson LM. ABM clinical protocol #21: Guidelines for breastfeeding and the drug-dependent woman. Breastfeed Med. 2009;4:225-228.

    Google Scholar 

  67. Ilett KF, Hackett LP, Gower S, et al. Estimated dose exposure of the neonate to buprenorphine and its metabolite norbuprenorphine via breastmilk during maternal buprenorphine substitution treatment. Breastfeed Med. 2012;7:269-274.

    Google Scholar 

  68. Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005;44:661-80.

    Google Scholar 

  69. Bogen DL, Perel JM, Helsel JC, et al. Estimated infant exposure to enantiomer-specific methadone levels in breastmilk. Breastfeed Med. 2011;6:377-384.

    Google Scholar 

  70. Geraghty B, Graham EA, Logan B, Weiss EL. Methadone levels in breast milk. J Hum Lact. 1997;13:227-230.

    Google Scholar 

  71. Lindemalm S, Nydert P, Svensson JO, et al. Transfer of buprenorphine into breast milk and calculation of infant drug dose. J Hum Lact. 2009;25:199-205.

    Google Scholar 

  72. Wojnar-Horton RE, Kristensen JH, Yapp P, et al. Methadone distribution and excretion into breast milk of clients in a methadone maintenance programme. Br J Clin Pharmacol. 1997;44:543-547.

    Google Scholar 

  73. McCarthy JJ, Posey BL. Methadone levels in human milk. J Hum Lact. 2000;16:115-120.

    Google Scholar 

  74. Gower S, Bartu A, Ilett KF, et al. The wellbeing of infants exposed to buprenorphine via breast milk at 4 weeks of age. J Hum Lact. 2014;30:217-223.

    Google Scholar 

  75. Welle-Strand GK, Skurtveit S, Jansson LM, et al. Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants. Acta Paediatr. 2013;102:1060-1066.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Comprehensive Pain Care, PC, Taylor Research, LLC, Marietta, Georgia

    Donald R Taylor

Authors
  1. Donald R Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donald R Taylor .

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Taylor, D.R. (2015). Special population: Pregnancy, pain and addiction. In: Managing Patients with Chronic Pain and Opioid Addiction. Adis, Cham. https://doi.org/10.1007/978-3-319-08111-3_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-08111-3_5

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-08110-6

  • Online ISBN: 978-3-319-08111-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation